| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 9.74▼ | 9.84▼ | 9.82▼ | 9.96▼ | 9.17▲ |
| MA10 | 9.88▼ | 9.94▼ | 9.91▼ | 9.64▼ | 8.49▲ |
| MA20 | 9.95▼ | 9.99▼ | 10.06▼ | 9.12▲ | 7.84▲ |
| MA50 | 10.19▼ | 9.84▼ | 9.70▼ | 8.15▲ | N/A |
| MA100 | 9.53▲ | 9.17▲ | 8.91▲ | 7.72▲ | N/A |
| MA200 | 8.89▲ | 8.50▲ | 8.18▲ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.044▼ | -0.064▼ | -0.079▼ | N/A | N/A |
| RSI | 39.903▼ | 42.526▼ | 42.778▼ | N/A | N/A |
| STOCH | 9.390▼ | 30.378 | 16.781▼ | 61.489 | 78.527 |
| WILL %R | -97.980▼ | -97.980▼ | -97.980▼ | -43.590 | -32.522 |
| CCI | -137.545▼ | -185.003▼ | -208.380▼ | 23.371 | 116.227▲ |
|
Wednesday, January 15, 2020 08:45 AM
IDEAYA Biosciences (NASDAQ:IDYA) announces key research highlights from its synthetic lethality pipeline. Methionine adenosyltransferase 2a (MAT2A) inhibitors for solid tumors with ...
|
|
Wednesday, January 15, 2020 07:52 AM
SOUTH SAN FRANCISCO, Calif., Jan. 15, 2020 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of ...
|
|
Wednesday, January 15, 2020 02:00 AM
/PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/01/20 | 9.81 | 10.11 | 9.43 | 9.43 | 49,500 |
| 21/01/20 | 9.90 | 10.20 | 9.70 | 9.70 | 35,700 |
| 17/01/20 | 10.04 | 10.25 | 9.68 | 10.03 | 75,200 |
| 16/01/20 | 10.85 | 10.964 | 9.55 | 10.04 | 68,500 |
| 15/01/20 | 10.25 | 11.30 | 9.593 | 10.58 | 102,500 |
| 14/01/20 | 10.21 | 10.91 | 9.70 | 10.23 | 69,700 |
| 13/01/20 | 9.176 | 10.96 | 9.176 | 10.01 | 42,000 |
| 10/01/20 | 8.87 | 9.995 | 8.87 | 9.27 | 66,140 |
| 09/01/20 | 8.23 | 8.76 | 8.14 | 8.62 | 36,600 |
| 08/01/20 | 8.90 | 9.145 | 8.36 | 8.46 | 24,600 |
|
|
||||
|
|
||||
|
|